| Identification | Back Directory | [Name]
Karenitecin | [CAS]
203923-89-1 | [Synonyms]
DB 172
BNP 1350
Cositecan
MCC 12824
Karenitecin
(4S)-4-Ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4S)- | [Molecular Formula]
C25H28N2O4Si | [MDL Number]
MFCD09833216 | [MOL File]
203923-89-1.mol | [Molecular Weight]
448.59 |
| Chemical Properties | Back Directory | [Boiling point ]
727.2±60.0 °C(Predicted) | [density ]
1.29±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
11.27±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Karenitecin is a topoisomerase I inhibitor, with potent anti-cancer activity. | [Definition]
ChEBI: Cositecan is a pyranoindolizinoquinoline. | [in vivo]
Karenitecin shows maximum growth inhibition of 61% on COLO320 cells and 54% on COLO205 colon cancer cells via i.p. administration of 1 mg/kg in mice. Karenitecin (1.0 mg/kg daily × 5 i.p.) significantly suppresses growth inhibition both in the parental Pgp-negative xenografts and in the Pgp-positive xenografts[2]. | [IC 50]
Topoisomerase I |
|
|